Ludwig-Maximilians-Universität München
Institute for Stroke and Dementia Research, University Hospital Munich
Dominik Paquet is a Professor at the Institute for Stroke and Dementia Research (ISD) of the University Hospital of LMU Munich, Germany. He received his PhD for work with Christian Haass at LMU Munich and performed postdoctoral work as a NYSCF Druckenmiller Fellow with Marc Tessier-Lavigne at Rockefeller University, where he developed efficient technologies to gene-edit iPSCs with CRISPR, differentiate them into human brain cells and model Alzheimer's disease. In 2017 Dr. Paquet established the PaquetLab (www.isd-research.de/PaquetLab) at ISD and currently serves as Professor of Neurobiology and core member of Synergy (www.synergy-munich.de), a leading Research Cluster of the Excellence Initiative of the German research funding organization. Using his broad background in neurodegenerative disease research, with specific training and expertise in molecular, stem cell and neurobiology, he leads an interdisciplinary team of neurobiologists, biochemists, and stem cell biologists. The PaquetLab uses cutting-edge technologies such as CRISPR genome editing, iPSC differentiation and human 3D tissue engineering to elucidate the molecular function of the human brain and the mechanisms leading to neurodegenerative and neurovascular diseases.

Moderator of 1 Session

Session Type
SYMPOSIUM
Date
Thu, 17.03.2022
Session Time
09:10 AM - 11:10 AM
Room
ONSITE: 113

Presenter of 1 Presentation

DEVELOPING IPSC-DERIVED HUMAN BRAIN TISSUE MODELS OF NEURODEGENERATIVE DISEASES

Session Type
SYMPOSIUM
Date
Thu, 17.03.2022
Session Time
09:10 AM - 11:10 AM
Room
ONSITE: 113
Lecture Time
10:25 AM - 10:40 AM

Abstract

Aims

Brain research heavily depends on models recapitulating key aspects of human brain physiology and disease pathology. Human iPSCs have great potential to complement existing disease models, as they allow directly studying affected human cell types. In addition, recent developments in CRISPR genome editing revolutionized how impacts of genetic alterations on disease formation can be investigated. Co-culture of disease-relevant iPSC-derived cells with disease-relevant mutations enables studying complex phenotypes involving cellular crosstalk.

Methods

Combining these technologies we established a new generation of iPSC-based human brain tissue models for neurodegenerative and neurovascular brain diseases. We successfully established a multicellular brain tissue model containing iPSC-derived cortical neurons, astrocytes, microglia, and recently also oligodendrocytes.

Results

Our technology provides highly controllable and reproducible 3-dimensional tissues with typical cell morphologies and functional features, including complex somatodendritic morphology of neurons, widespread synapse formation, spontaneous and induced electrical activity, network formation, microglial ramification and tiling etc. Tissues can be cultured for over 12 months in a postmitotic state without signs of proliferation or cell death, thus providing a more controllable, reproducible, and long-lived alternative to cortical organoids currently used for 3D disease modelling. To establish human models of AD, FTD-Tau, or neurovascular diseases, we used our efficient CRISPR pipeline to introduce synergistic disease-associated mutations to accelerate naturally occurring disease processes and promote pathology. We will present a first phenotypic characterization of our multicellular tissue models.

Conclusions

We expect that these models will support studies elucidating novel, potentially human-specific pathomechanisms and provide a human framework for translation and screening.

Hide